NCT06930677 Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200
| NCT ID | NCT06930677 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Next Biomedical Co., Ltd. |
| Condition | Knee Osteoarthritis (Knee OA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2025-04-17 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2025-04-17 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Study in patients with knee osteoarthritis treated by embolization using NBGM200
Eligibility Criteria
Inclusion Criteria: * Osteoarthritis proven by MR-imaging Exclusion Criteria: * Current local infection * Life expectancy less than 6 months
Frequently Asked Questions
Who can join the NCT06930677 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Knee Osteoarthritis (Knee OA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06930677 currently recruiting?
Yes, NCT06930677 is actively recruiting participants. Visit ClinicalTrials.gov or contact Next Biomedical Co., Ltd. to inquire about joining.
Where is the NCT06930677 trial being conducted?
This trial is being conducted at Ghent, Belgium, Leuven, Belgium, Tilburg, Netherlands.
Who is sponsoring the NCT06930677 clinical trial?
NCT06930677 is sponsored by Next Biomedical Co., Ltd.. The trial plans to enroll 72 participants.